$VTVT looking at PTGX, Rusfertide drug that let's patients avoid Polycythemia. If a lift on Full Clinical Hold can take this company to 1.6B market cap. Where will we be when we get confirmation that TPP399 works as intended without major side effects? I say we hit 2B at some stage.
5
3
3 Likes